CareCloud Just Printed Its Best Quarter Ever — and the Tape Yawned

Record EPS, 50.5% gross margin, 89% of earnings to common holders. A $92M market cap still trading 83% below its 2020 peak is waiting for a second act.

CCLD · Earnings Call · 2026-11-05

The record is real; the re-rating is not

CareCloud's Q3 2026 call opened with a line that would normally move a micro-cap: “the third quarter was the most profitable quarter in CareCloud's history” — Stephen Snyder, Chief Executive Officer · 2026-11-05. Revenue rose 9% to $33.7M, GAAP net income jumped 54% to $4.7M, EPS hit $0.10, and adjusted EBITDA reached $9.9M. For a company with a $91.8M market cap, those are not cosmetic numbers. Yet the stock is down 4.8% over the last 90 days and sits 18.8% below its late-August peak of $2.66. The full tape is harsher still: a 2020 peak of $12.53 and an 82.8% drawdown since. The market is treating this as a "show me" quarter, not an inflection. The reason is simple: guidance was reaffirmed, not raised. Full-year revenue is still $128M–$132M, adjusted EBITDA $29M–$31M, EPS $0.20–$0.23. With nine-month revenue at $96.9M, the implied Q4 midpoint is roughly $33.1M — slightly below Q3. Management flagged seasonality and told analysts to be modest. After a Q2 call where they promised the second half would be “much stronger than the first half of the year” — Stephen Snyder, Chief Executive Officer · 2026-08-06, Q3 delivered the first half of that promise. Q4 has to prove it wasn't a peak.

AI is finally showing up in the cost line

The most important part of this call was not the record earnings headline; it was the operating detail underneath. CareCloud has talked about its AI Center of Excellence and its stratusAI and cirrusAI stacks for several quarters. This time management quantified the payoff. AI and automation cut manual claim touches by roughly 44% in the RCM division that serves most clients, with zero-touch processing rising to 84% from 74%. The denial rate fell below 4% from about 8%, against an industry benchmark of 6%–8%. The AI prior-authorization product is live with a pilot client, connected to 105 payers, and “cut submission time from about 15 minutes to under 2” — A. Chaudhry, Chief Strategy Officer · 2026-11-05, with a 91% initial pass rate across more than 600 submissions. That is the kind of proof that separates an AI narrative from an AI margin. Gross margin expanded to 50.5% from 47.8%, and adjusted EBITDA margin reached roughly 29% from 25%. Bonnie Boyer, in her first call as CFO, framed it as operating leverage: “total operating expenses came down about 2.5% year-over-year to $27.2 million, while revenue grew 9%” — Bonnie Boyer, Chief Financial Officer · 2026-11-05. Direct operating costs rose only 3%. The denial prediction and medical coding services layers are no longer slideware; they are part of the cost base, and the cirrusAI Notes ambient documentation app is now embedded in the Wellsoft emergency-department install base. But the sustainability question is unresolved. Analyst Lisa Thompson pressed: if expenses are this low, is this the bottom? Management said directionally yes, but repeatedly invoked seasonality and would not guide 2027. The Q3 margin may be a genuine step-up, or it may be the high-water mark of a cost-cutting year. The stock is voting for the latter until proven otherwise.

The capital structure is now a common-shareholder story

The second engine is financial, not operational. CareCloud spent two years unwinding a preferred-heavy capital structure. In May it redeemed the Series B; the quarterly preferred dividend fell to $538,000 from about $1.4M a year earlier — an 86% reduction from two years back. Roughly 89% of Q3 net income reached common shareholders, versus 55% a year ago. That is why $4.7M of net income became $4.2M attributable to common and $0.10 of EPS — matching all of 2025 in a single quarter.

Record earnings are only half of the story. The other half is who those earnings now belong to.
Stephen Snyder, Chief Executive Officer · 2026-11-05

The balance sheet is moving the right way, but it is still a leveraged small-cap. The term loan stood at $36.7M on September 30 and $34.2M by November 2; the $9M revolver draw was fully repaid. Net debt was $32.7M, or about 1.1x trailing adjusted EBITDA. The common shareholder now owns far more of the earnings stream, but the debt-funded redemption means the first call on cash is still debt paydown — not buybacks, not a dividend. Management's stated order is invest in AI, reduce debt, then selective tuck-ins. Prudent, and it caps the near-term equity story. Valuation reflects the ambiguity. At roughly 1.2x revenue and about 7x free cash flow less stock comp, CareCloud looks cheap against healthcare IT peers — if Q3 is the new run rate. The last filed quarter showed total revenue of $31M and an operating margin of 3.2%; the Q3 call runs two quarters ahead of that filing. If the Q3 margin holds, the multiple is too low. If it mean-reverts, the market is right.

Growth is still cross-sell — and that is the tell

The new growth engines are real but early. KabaFusion, a national home-infusion provider, selected CareCloud to build LailaCare, an AI-native platform spanning referral intake, authorization, patient engagement and revenue cycle. CareCloud recognized its first revenue from that work in Q3. It is a promising template: private-equity-backed healthcare platforms paying CareCloud to build the system they run on, not merely to run their RCM. Medsphere contributed $6.3M and is largely integrated; the near-term opportunity there is wallet share and critical-access hospitals, not a new-logo bonanza. The other engine is compliance. Empower, acquired in May for about one-third of trailing revenue, reversed more than $1 million in alleged payer overpayments for a client and has already generated RCM signings with an MSO and a wound care practice. CareCloud named Empower's founder Chief Compliance Officer and plans to launch a subscription software compliance offering later this quarter. Bonnie called it high-margin, low-capital and sticky. That is the right kind of revenue. But notice what is missing: net new customer wins. The new business theme slid this quarter, and the call leaned on cross-sell, wallet share and existing enterprise relationships. Allen Klee asked whether medSR, the project-based IT consulting business, was stabilizing; Stephen Snyder said “we view that as stabilizing sequentially” — Stephen Snyder, Chief Executive Officer · 2026-11-05. Better than shrinking, but not growth. The sales force was tripled a year ago expressly to cross-sell into the existing base — and the jury is still out on whether that produces durable net new logos or just deeper penetration of a maturing base.

The market wants a second act

CareCloud has done the hard part: it turned a preferred-laden, loss-making healthcare IT roll-up into a GAAP-profitable, cash-generating business with a cleaner capital structure. The Q3 print proves the model can produce real margins. But the tape says the market needs more than one record quarter — Q4 has to hold, 2027 guidance has to show growth, and the AI and compliance engines have to scale beyond a single KabaFusion or a handful of Empower referrals. The prior calls show management laying this groundwork for years. In May, Hadi called the Series B redemption “the single biggest capital structure simplification in our history” — A. Chaudhry, Chief Strategy Officer · 2026-05-07. In March, Stephen said the company could hit its AI goals “with a leaner team than we had initially envisioned” — Stephen Snyder, Chief Executive Officer · 2026-03-12. Q3 is the first quarter where both promises show up in the same P&L. That is progress. But for a $92M market cap still 83% below its 2020 peak, progress is not the same as a re-rating. The next quarter must show the margin is durable and the growth engines are repeatable — not just that the cost cuts were real.